Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study to Estimate the Safety and Tolerability of the Combination of Polatuzumab Vedotin, With or Without Glofitamab, With Dose Adjusted Rituximab, Etoposide, Cyclophosphamide, and Doxorubicin (PERCH) for Upfront Treatment of Aggressive B-Cell Non-Hodgkin Lymphomas

NCT04231877 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT04231877
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04231877 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study to Estimate the Safety and Tolerability of the Combination of Polatuzumab Vedotin, With or Without Glofitamab, With Dose Adjusted Rituximab, Etoposide, Cyclophosphamide, and Doxorubicin (PERCH) for Upfront Treatment of Aggressive B-Cell Non-Hodgkin Lymphomas
Lead sponsor
University of Washington
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 27, 2020
Completion date
December 1, 2031
Enrollment
56 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aggressive non-hodgkin lymphoma, alk-positive large b-cell lymphoma, diffuse large b-cell lymphoma, not otherwise specified, ebv-positive diffuse large b-cell lymphoma, not otherwise specified, gray-zone lymphoma, high grade b-cell lymphoma with myc and bcl2 and/or bcl6 rearrangements, high grade b-cell lymphoma, not otherwise specified, primary mediastinal large b-cell lymphoma, t-cell/histiocyte-rich large b-cell lymphoma